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Differential Relationship between Metabolic Syndrome Score 
and Severity of Coronary Atherosclerosis as Assessed by 
Angiography in a Non-Diabetic and Diabetic Korean Population
Whether the metabolic syndrome (MetS) has prognostic value for coronary artery disease 
(CAD) beyond its individual components is controversial. We compared the relationship 
between the number of MetS components and CAD severity as assessed by angiography in 
non-diabetic and diabetic subjects. We consecutively enrolled 527 patients who underwent 
their first coronary angiography. Patients were divided into four groups according to the 
number of MetS components: 0/1, 2, 3, and 4/5. A coronary atherosclerosis score was 
used to quantify the extent of atherosclerotic involvement. The relationship between the 
MetS score and angiographic CAD severity or clinical presentation was compared between 
non-diabetic and diabetic subjects. Individuals with the MetS (n = 327) had a higher 
prevalence of CAD (60% vs 32%, P < 0.001), multi-vessel disease (34% vs 16%, P < 
0.001), and acute coronary syndromes (49% vs 26%, P < 0.001) than those without the 
MetS. In the non-diabetic group, atherosclerosis score increased with the MetS score (1.0 
± 2.1, 2.0 ± 2.9, 2.8 ± 2.9, and 3.6 ± 3.9, P < 0.001) whereas there was no significant 
difference in the diabetic group (0.5 ± 1.0, 5.2 ± 4.7, 4.2 ± 2.9, and 4.4 ± 3.5, P = 
0.102). The MetS score is related to CAD severity in non-diabetic patients but the 
association between the MetS score and angiographic CAD severity may be obscured in the 
presence of diabetes.
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The metabolic syndrome (MetS) is characterized by visceral ad-
iposity, insulin resistance, dyslipidemia and increased blood 
pressure. It is not a single disease but a cluster of risk factors for 
atherosclerotic coronary artery disease (CAD) (1, 2). Consequent-
ly, the MetS has come to the fore as a major risk factor of CAD 
(3, 4). Isomaa et al. (5) reported that patients with the MetS had 
a higher incidence of CAD and increased all-cause mortality than 
those without it, but other researchers failed to verify these rela-
tionships (6, 7). Thus, unlike diabetes mellitus, which is a well-
known established risk factor for CAD (8, 9), whether MetS has 
an additive impact on the development of CAD in addition to 
its individual components (e.g., hypertension, diabetes) is con-
troversial (10). Conversely, it has been reported that the sum-
mation of the constituents of the MetS, the MetS score, is relat-
ed to a higher incidence of CAD (11, 12). 
  The authors reported previously that epicardial fat measured 
by echocardiodraphy is related to the extent of coronary athero-
sclerosis in patients undergoing their first coronary angiography 
(13). From the data, we evaluated the relationship between the 
MetS score and CAD severity as assessed by angiography ac-
cording to the presence of diabetes. Whether the MetS predicts 





We collected clinical, biochemical, and angiographic informa-
tion for 527 consecutive patients aged > 18 yr (267 males; mean 
age, 58.4 ± 10.8 yr) who underwent their first coronary angiog-
raphy due to chest pain between January 2005 and October 2005 
at Ajou University Medical Center. The medical records of all pa-
tients were reviewed. Patients were excluded if they had a his-
tory of percutaneous coronary intervention, coronary artery by-
pass graft, acute ST-segment elevation myocardial infarction, 
active inflammation, heart failure, chronic kidney disease, se-
vere liver disease or cancer. 
  Anthropometric measurements such as the body mass index 
(BMI), waist circumference and hip circumference were collect-
ed. Plasma lipid profiles and levels of C-reactive protein (CRP), Yoon S-E, et al.  •  Metabolic Syndrome Score and Coronary Atherosclerosis
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fibrinogen, uric acid and cardiac enzymes were measured. The 
homeostasis model assessment of insulin resistance (HOMA-
IR) was calculated in non-diabetic patients using fasting plasma 
insulin concentrations and glucose concentrations as previous-
ly described (14). Patients with more than three of five criteria 
based on the updated guidelines issued by the Adult Treatment 
Panel (ATP III) of the National Cholesterol Education Program 
were considered to have the MetS. Central obesity was consid-
ered to be present if the waist circumference was > 90 cm in men 
and > 80 cm in women; these are the threshold values for Asian 
populations (15, 16). The MetS score was defined as the num-
ber of MetS components present. 
Angiographic studies
On quantitative analyses of coronary angiograms (Quantcor QCA, 
version 4.0; Pie Medical Imaging, Maastricht, The Netherlands), 
the presence of stenosis ≥ 50% in diameter of major epicardial 
vessels was defined as CAD. The extent of CAD was quantified 
using the number of vessels with ≥ 50% stenosis and a coronary 
atherosclerosis score as follows (17). The coronary artery tree 
was divided into nine segments: left main coronary artery; prox-
imal, mid-, and distal left anterior descending artery; proximal 
circumflex artery (including the first obtuse marginal branch); 
circumflex artery distal to the first marginal branch; proximal 
and mid-right coronary artery; posterior descending artery. Each 
of these segments was scored from 0 to 3 depending on the most 
severe stenosis according the following system: 0 = normal; 1 = 
stenosis of 1%-49%; 2 = stenosis of 50%-99%; and 3 = total occlu-
sion. A coronary atherosclerosis score was generated as the sum 
of the scores in all segments.
Statistical analyses
SPSS version 17.0 (SPSS Incorporated, Chicago, IL, USA) was 
used for statistical analyses. Continuous variables were expressed 
as mean and standard deviation, and categorical variables as 
number and percentage. Comparisons of differences in anthro-
pometric and biochemical values, and frequencies of CAD risk 
factors, CAD, and multi-vessel disease according to the presence 
of the MetS were undertaken using the Student’s t-test and chi-
squared test. Correlations of the MetS score with various clinical 
and biochemical parameters were examined by the Spearman’s 
rank correlation analysis. Using one-way analysis of variance, 
the relationship between the MetS score and the extent of coro-
nary atherosclerosis was explored in diabetic and non-diabetic 
subjects. A set of well-recognized risk factors for CAD (age; his-
tory of hyperlipidemia, hypertension, and diabetes; family his-
tory of early atherosclerotic CAD; current smoking; and elevat-
ed levels of CRP ≥ 1 mg/L) were included in a logistic regression 
model of angiographic CAD (1, 17). The presence of the MetS 
was then added to this model to determine if there was an addi-
tional predictive value. Statistical significance was considered 
at P < 0.05. 
Ethics statement
The study protocol was approved by the institutional review board 
of Ajou University Medical Center (Suwon, Korea, IRB approval 
number: 4-2005-013-0). All patients provided written informed 




A summary of anthropometric, biochemical, and clinical char-
acteristics according to the presence of the MetS is shown in 
Table 1. A total of 327 (62%) patients had the MetS, and 447 (85%) 
patients had more than two components of the MetS. The mean 
MetS score was 2.8 ± 1.3. Among patients with the MetS, an ele-
vated fasting glucose level (85.6%) was the most frequent com-
ponent followed by high blood pressure (85.3%), waist circumfer-
ence (77.7%), high-density lipoprotein (HDL) cholesterol (61.2%) 
and triglyceride (TG; 56.3%). The HOMA-IR of non-diabetic pa-
tients (n = 402) was elevated in those with the MetS. The level of 
CRP was higher in those with the MetS. No difference was found 
Table 1. Clinical characteristics and laboratory data according to the presence or ab-
sence of the metabolic syndrome (MetS)
Parameters MetS (-) 
(n = 200)
MetS (+)  
(n = 327) P value
Age (yr)   55.6 ± 11.6   60.1 ± 9.9 < 0.001
Males, No. (%) 112 (56) 155 (47) 0.056
BMI (kg/m²) 23.7 ± 2.8   26.0 ± 2.9 < 0.001
Waist circumference (cm) 84.1 ± 8.5   92.7 ± 8.1 < 0.001
Hip circumference (cm) 93.2 ± 8.4   98.7 ± 7.3 < 0.001
Waist-hip ratio   0.90 ± 0.08     0.94 ± 0.06 < 0.001
Systolic BP (mmHg) 123 ± 17   130 ± 19 < 0.001
Diastolic BP (mmHg)   77 ± 10     79 ± 11 0.012
Smoking, No. (%) 70 (35) 106 (32) 0.054
Hypertension, No. (%) 63 (32) 229 (70) < 0.001
Diabetes mellitus, No. (%)  18 (9.5)    107 (32.7) < 0.001
Total cholesterol (mg/dL) 168.5 ± 34.6   176.7 ± 37.7 0.013
LDL-cholesterol (mg/dL)   97.5 ± 29.4   100.1 ± 32.7 0.354
Triglyceride (mg/dL) 107.4 ± 61.4   178.6 ± 96.9 < 0.001
HDL-cholesterol (mg/dL)   50.7 ± 12.1     42.3 ± 10.1 < 0.001
Glucose (mg/dL) 106.5 ± 33.2   122.1 ± 37.1 < 0.001
Uric acid (mg/dL)   4.9 ± 1.5     5.5 ± 2.8 0.016
Fibrinogen (mg/dL) 339.3 ± 95.0 369.2 ± 5.7 0.001
HOMA-IR*   1.85 ± 0.13     3.01 ± 0.16 0.001
CRP (mg/L)   1.86 ± 0.26     2.82 ± 0.30 0.016
ACS, No (%) 52 (26) 160 (49) < 0.001
Angiographic CAD, No. (%) 64 (32) 196 (60) < 0.001
Multi-vessel disease, No. (%) 31 (16) 110 (34) < 0.001
Data are expressed as mean ± standard deviation (SD) or frequency (%). All variables 
were analyzed using Student’s t-test and chi-squared test. *The homeostasis model 
assessment of insulin resistance (HOMA-IR) was calculated only for non-diabetic pa-
tients (n = 402). ACS, acute coronary syndrome; BMI, body mass index; BP, blood 
pressure; CAD, coronary artery disease; HDL; high-density lipoprotein; LDL, low-den-
sity lipoprotein.Yoon S-E, et al.  •  Metabolic Syndrome Score and Coronary Atherosclerosis
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in the level of low-density lipoprotein (LDL) cholesterol between 
the two groups.
Relationship between the MetS score and anthropometric, 
biochemical and angiographical variables
Spearman’s rank correlation analysis showed that the MetS score 
was positively associated with age, weight, waist circumference, 
blood pressure, the HOMA-IR, as well as levels of total choles-
terol (TC), TG, glucose, insulin, uric acid, CRP and fibrinogen, 
and negatively associated with the HDL-cholesterol level (Table 
2). There was no association between the MetS score and LDL-
cholesterol level. The degree of correlation between the MetS 
score and TG level was highest, followed by that with HDL cho-
lesterol, waist circumference, BMI, and HOMA-IR. 
Relationship between the MetS score and severity of 
coronary atherosclerosis according to the presence of 
diabetes
A total of 195 of 260 CAD patients (75%) had the MetS. The fre-
quency of CAD and multi-vessel disease was higher in patients 
with the MetS compared with those without it (60% vs 32%, P < 
0.001; 34% vs 16%, P < 0.001, respectively). Participants with at 
least two components of the MetS who did not meet the criteria 
for the definition of the MetS had a higher frequency of angio-
graphic CAD (55% vs 16%, P < 0.001) and multi-vessel disease 
(30% vs 8%, P < 0.001) and a greater atherosclerosis score (3.3 ± 
3.4 vs 1.0 ± 2.0, P < 0.001) in comparison with those with less than 
one MetS component. Patients with the MetS and diabetes had 
the highest coronary atherosclerosis score, followed by diabetic 
patients without the MetS, the MetS without diabetes, and pa-
tients with neither diabetes nor the MetS (4.5 ± 3.3, 3.8 ± 4.3, 3.1 
± 3.4, and 1.6 ± 2.8, respectively) (Fig. 1). On multiple logistic re-
gression analysis, the MetS was independently associated with 
angiographic CAD (Table 3). In the overall population, the fre-
quency of CAD, multi-vessel disease, coronary atherosclerosis 
score, and CRP level increased with MetS score (Table 4). These 
Table 2. Correlation of the metabolic syndrome (MetS) score with anthropometric, 
biochemical and angiographical variables 
Variables r P value 
Body mass index  0.376 < 0.001
Age 0.243 < 0.001
Weight 0.226 < 0.001
Waist 0.459 < 0.001
Waist-hip ratio 0.264 < 0.001
Systolic blood pressure 0.231 < 0.001
Diastolic blood pressure 0.188 < 0.001
Total cholesterol 0.121 0.006
LDL 0.045  0.305
Triglyceride 0.501 < 0.001
HDL -0.474 < 0.001
Glucose* 0.264 < 0.001
Insulin* 0.256 < 0.001
HOMA-IR* 0.288 < 0.001
Uric acid 0.154 < 0.001
Log C-reactive protein 0.238 < 0.001
Fibrinogen 0.183 < 0.001
Coronary atherosclerosis sore 0.313 < 0.001
Number of vessels ≥ 50% stenosis 0.334 < 0.001
Correlations of the MetS score with various clinical and biochemical parameters were 
examined by the Spearman’s rank correlation analysis. *Correlation of metabolic syn-
drome score with fasting insulin, glucose concentrations and homeostasis model as-
sessment of insulin resistance (HOMA-IR) was analyzed only in non-diabetic patients 
(n = 402). HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 3. Multiple logistic analyses of risk factors for coronary artery disease including 
the metabolic syndrome for angiographic coronary artery disease
Risk factors Odds ratio (95% CI) P value
Age 
   Male ≥ 45 yr







Hypertension 1.763 (1.148-2.707) 0.01
Smoking 1.609 (1.038-2.495) 0.033
LDL cholesterol ≥ 130 mg/dL 1.051 (0.652-1.693) 0.84
C-reactive protein ≥ 1 mg/L 1.792 (1.193-2.691) 0.005
Diabetes mellitus 2.225 (1.193-2.691) 0.005
Metabolic syndrome 1.901 (1.216-2.973) 0.005
All variables were analyzed using multiple logistic analysis. LDL, low-density lipopro-
tein; CI, confidence interval.
Fig. 1. Coronary atherosclerosis score according to the presence of the metabolic 
syndrome (MetS) or diabetes mellitus (DM). *vs MetS(+)DM(-), MetS(+)DM(+), P < 
0.001, vs MetS(-)DM(+), P = 0.035; 
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Table 4. Extent and clinical presentation of coronary artery disease (CAD) in relation 










4, 5  
(n = 167)
AS score 0.9 ± 2.0 2.4 ± 3.6 3.1 ± 2.9 4.1 ± 3.7 < 0.001
CAD, No. (%) 16 (20) 51 (43) 89 (56) 107 (64) < 0.001
MVD, No. (%)   6 (11) 25 (21) 42 (26)   68 (41) < 0.001
ACS, No. (%) 6 (8) 45 (38) 72 (45)   88 (53) < 0.001
CRP (mg/L) 1.3 ± 1.9 1.9 ± 3.1 2.3 ± 3.6 2.9 ± 5.1 0.016
Data are expressed as mean ± standard deviation (SD) or frequency (%). All variables 
were analyzed using one-way analysis of variance and chi-squared test. ACS, acute 
coronary syndrome; AS, atherosclerosis; CRP, C-reactive protein; MVD, multi-vessel 
disease.Yoon S-E, et al.  •  Metabolic Syndrome Score and Coronary Atherosclerosis
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relationships persisted in non-diabetic individuals, whereas no 
relationship was found between the MetS score and coronary 
angiographic atherosclerosis in diabetic patients (Table 5). 
Relationship between the MetS and disease activity
As the MetS score increased, so did the frequency of acute cor-
onary syndromes and CRP level (Table 4). Patients presenting 
with ACS (n = 212) had higher MetS scores compared with those 




The aim of the present study was to investigate the relationship 
between the MetS score and CAD severity according to angiog-
raphy and to determine if it differed based on the presence of 
diabetes. The MetS score influenced the severity of coronary ath-
erosclerosis in non-diabetic patients, but there was no relation-
ship between the MetS score and coronary atherosclerosis in 
diabetic subjects.
  The MetS is determined by the presence of ≥ 3 quantitatively 
identified markers. It has been regarded to be an important risk 
factor for CAD and a predictor for cardiovascular events (1-5). 
Some authors have raised the question of whether it has addi-
tive prognostic value for CAD in tandem with its individual com-
ponents. It was suggested that attempts to define a criteria of the 
MetS that simultaneously predicts for CAD and diabetes are un-
helpful because the MetS had weak or no association with car-
diovascular risk (6, 10, 18, 19). Those findings indicated that the 
MetS is a marker of CAD risk, but not above and beyond the risk 
associated with its individual components. In our cohort, elevat-
ed fasting glucose level and high blood pressure were the most 
frequently encountered factors in patients with the MetS. Our 
findings coincided with studies in which high blood pressure 
and a high fasting blood glucose level were strongly related to 
cardiovascular mortality among individual MetS components 
(10). The MetS remained an independently associated factor 
for angiographic CAD on multiple logistic regression analysis. 
Thus, glycemic level and high blood pressure are the most criti-
Table 5. Relationship between the metabolic syndrome (MetS) score and the angiographic severity of coronary artery disease (CAD) and to disease activity dependent upon the 
presence of diabetes
Parameters
Non-diabetic subjects (n = 402)  
MetS score  P value
Diabetic subjects (n = 125)  
MetS score  P value
0, 1 (n = 76) 2 (n = 105) 3 (n = 128) 4, 5 (n = 93) 0, 1 (n = 4) 2 (n = 15) 3 (n = 32) 4, 5 (n = 74)
AS score 1.0 ± 2.1 2.0 ± 2.9 2.8 ± 2.9 3.6 ± 3.9 < 0.001 0.5 ± 1.0 5.2 ± 4.7 4.2 ± 2.9 4.6 ± 3.5 0.102
CAD, No. (%)  13 (17) 41 (39) 65 (51) 52 (56) < 0.001 0 10 (67) 24 (75) 55 (74) 0.014
MVD, No. (%)  6 (8) 18 (17) 28 (22) 36 (64) < 0.001 0   7 (47) 14 (44) 32 (43) 0.085
ACS, No. (%)  7 (9) 39 (37) 52 (41) 42 (45) < 0.001 0   6 (40) 20 (63) 46 (62) 0.003
CRP (mg/L) 1.3± 2.0 1.8 ± 3.2 2.3 ± 5.1 2.1 ± 3.8     0.095 0.9 ± 0.4 2.2 ± 2.7 2.3 ± 3.4 2.8 ± 4.3 0.577
Data are expressed as mean ± standard deviation (SD) or frequency (%). Using one-way analysis of variance and chi-squared test, the relationship between the MetS score 
and the extent of coronary atherosclerosis was explored in diabetic and non-diabetic subjects. ACS, acute coronary syndrome; AS, atherosclerosis; CRP, C-reactive protein, 
MVD, multi-vessel disease.
cal components of the MetS for the development of CAD, and 
the MetS might have an additive effect on the severity of coro-
nary atherosclerosis beyond that of its individual components.
  We also sought to investigate the usefulness of counting indi-
vidual factors of the MetS for prediction of CAD. Increasing MetS 
score was significantly related to increasing coronary atheroscle-
rosis score, consistent with the results of other studies (11, 12). 
Patients with more than two components of the MetS not fulfill-
ing the criteria for the diagnosis of the MetS had a higher athero-
sclerosis score and more multi-vessel disease than subjects with 
one or fewer than one component of the MetS. Counting the 
components of the MetS appears to be more valuable for risk 
stratification for CAD than dichotomously diagnosing the MetS 
if there are more than three arbitrary components. To verify the 
relationship between the MetS score and coronary atheroscle-
rosis in diabetes, we divided the study cohort into two groups 
based on the presence of diabetes. In non-diabetic subjects (n = 
402), the relationship between the MetS score and the severity 
of coronary atherosclerosis persisted, whereas there was no such 
association in diabetic subjects (n = 125). These findings might be 
due to attenuation of the impact of the MetS on the development 
of CAD by the presence of diabetes (a well-recognized strong 
risk factor for CAD). Similarly, Zornitzki et al. (7) showed that 
only diabetes (and not the MetS) predicted the severity and ex-
tent of CAD in women. Therefore, the MetS score does not seem 
to be useful for prediction of the extent of CAD in the presence 
of diabetes.
  It has been reported that the MetS imparts an increased risk 
of cardiovascular events after the first myocardial infarction (20). 
Lee et al. (21) showed that the MetS was an important predictor 
for in-hospital death in patients with ST-elevation myocardial 
infarction. CRP as a marker of vascular inflammation may have 
a role in increasing CAD activity as well as in promoting coro-
nary atherosclerosis (17, 22, 23). Ridker et al. (24) demonstrated 
that the MetS score was well correlated with the CRP level, which 
is consistent with our results. Patients with acute coronary syn-
drome had a higher MetS score than those with atypical chest 
pain or stable angina. These findings suggest that accumulating 
individual components of the MetS may increase vascular in-Yoon S-E, et al.  •  Metabolic Syndrome Score and Coronary Atherosclerosis
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flammation, leading to heightened CAD activity. Thus, the MetS 
score and CRP level are closely related. The MetS score and CRP 
level could help us better predict future cardiovascular events in 
patients with established CAD as well as in those without CAD. 
  The present study had several limitations. First, the study group 
contained only Korean patients undergoing their first coronary 
angiography due to chest pain. Second, the design of our study 
was cross-sectional. Third, the coronary atherosclerosis score 
does not represent the actual atheroma volume or plaque bur-
den; it is a crude method for estimating CAD severity. However, 
coronary angiography is the most widely used technique for as-
sessing coronary anatomy, and this score was validated in a study 
that compared CRP level with the extent of CAD (17).
  In conclusion, the MetS score can be readily obtained and cal-
culated in most clinical situations. Although the association be-
tween the MetS score and angiographic CAD severity may be 
obscured by the presence of diabetes, the MetS score is related 
to the severity of coronary atherosclerosis in non-diabetic pa-
tients. Calculating the MetS score might provide additive infor-
mation for predicting the extent of CAD in non-diabetic patient 
with angina.
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The metabolic syndrome (MetS) and its individual components are regarded as an important factor for the development of 
atherosclerotic coronary artery disease (CAD). Here we investigated the influence of the presence of diabetes on the relationship 
between number of MetS components the CAD severity in 527 patients who underwent their first coronary angiography. 
Interestingly, in the non-diabetic group, atherosclerosis score increased with MetS score whereas there was no significant 
difference in the diabetic group. Although diabetes itself is a powerful risk factor for CAD, the association between MetS score and 
angiographic CAD severity may be obscured in the presence of diabetes.